Donald Banerji
- Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 studyBy Edward Kerwin, Jacques Hébert, Nicola Gallagher, Carmen Martin, Tim Overend, Vijay K.T. Alagappan, Yimeng Lu and Donald BanerjiEdward Kerwin*Clinical Research Institute of Southern Oregon, PC, Medford, ORJacques Hébert#Centre de Recherche Appliquée en Allergie de Québec, Québec, QC, CanadaNicola Gallagher¶Novartis Horsham Research Centre, Horsham, UKCarmen Martin¶Novartis Horsham Research Centre, Horsham, UKTim Overend¶Novartis Horsham Research Centre, Horsham, UKVijay K.T. Alagappan+Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAYimeng Lu+Novartis Pharmaceuticals Corporation, East Hanover, NJ, USADonald Banerji+Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
- Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyBy Eric D. Bateman, Gary T. Ferguson, Neil Barnes, Nicola Gallagher, Yulia Green, Michelle Henley and Donald BanerjiEric D. Bateman1Dept of Medicine, University of Cape Town, Cape Town, South AfricaGary T. Ferguson2Pulmonary Research Institute of Southeast Michigan, Livonia, MINeil Barnes3London Chest Hospital, Barts Health NHS Trust, LondonNicola Gallagher4Novartis Horsham Research Centre, Horsham, UKYulia Green4Novartis Horsham Research Centre, Horsham, UKMichelle Henley4Novartis Horsham Research Centre, Horsham, UKDonald Banerji5Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
- Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE studyBy Donald A. Mahler, Marc Decramer, Anthony D'Urzo, Heinrich Worth, Tracy White, Vijay K.T. Alagappan, Hungta Chen, Nicola Gallagher, Károly Kulich and Donald BanerjiDonald A. Mahler1Section of Pulmonary and Critical Care Medicine, Geisel School of Medicine at Dartmouth, Hanover, NH, USAMarc Decramer2Division of Respiratory Medicine, University Hospital, Katholieke Universiteit, Leuven, BelgiumAnthony D'Urzo3Dept of Family and Community Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, CanadaHeinrich Worth4Dept of Pneumology and Cardiology, Hospital Fürth, University Erlangen-Nürnberg, Fürth, GermanyTracy White5Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAVijay K.T. Alagappan5Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAHungta Chen5Novartis Pharmaceuticals Corporation, East Hanover, NJ, USANicola Gallagher6Novartis Horsham Research Centre, Horsham, UKKároly Kulich7Novartis Pharma AG, Basel, SwitzerlandDonald Banerji5Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
- QVA149 administered once daily provides significant improvements in lung function over 1 year in patients with COPD: The ENLIGHTEN studyBy Ronald Dahl, Kenneth Chapman, Michael Rudolf, Rajendra Mehta, Pearl Kho, Vijay Alagappan, Indrias Berhane, Hungta Chen and Donald BanerjiRonald Dahl1Dept of Respiratory Diseases, Aarhus University Hospital, Aarhus, DenmarkKenneth Chapman2Asthma and Airway Centre, University Health Network, Toronto Western Hospital, Toronto, CanadaMichael Rudolf3Dept of Respiratory Medicine, Ealing Hospital NHS Trust and Imperial College, London, United KingdomRajendra Mehta4Allergy and Asthma Care, Allergy and Asthma Care and Research Centre, Indore, IndiaPearl Kho5Novartis Horsham Research Centre, Novartis, Horsham, United KingdomVijay Alagappan6Novartis Pharmaceuticals Corporation, Novartis, East Hanover, NJ, United StatesIndrias Berhane6Novartis Pharmaceuticals Corporation, Novartis, East Hanover, NJ, United StatesHungta Chen6Novartis Pharmaceuticals Corporation, Novartis, East Hanover, NJ, United StatesDonald Banerji6Novartis Pharmaceuticals Corporation, Novartis, East Hanover, NJ, United States
- Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: The SHINE studyBy Eric Bateman, Gary T. Ferguson, Neil Barnes, Nicola Gallagher, Yulia Green, Rachael Horton, Michelle Henley and Donald BanerjiEric Bateman1Department of Medicine, University of Cape Town, South AfricaGary T. Ferguson2Pulmonary Department, Pulmonary Research Institute of Southeast Michigan, Livonia, MI, United StatesNeil Barnes3London Chest Hospital, Barts Health NHS Trust, London, United KingdomNicola Gallagher4Respiratory Department, Novartis Horsham Resarch Centre, Horsham, United KingdomYulia Green4Respiratory Department, Novartis Horsham Resarch Centre, Horsham, United KingdomRachael Horton4Respiratory Department, Novartis Horsham Resarch Centre, Horsham, United KingdomMichelle Henley4Respiratory Department, Novartis Horsham Resarch Centre, Horsham, United KingdomDonald Banerji5Respiratory Department, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- Safety and efficacy of NVA237 once daily in Japanese patients: The GLOW4 trialBy Mitsuaki Sekiya, Tomotaka Kawayama, Yoshinosuke Fukuchi, Yota Takahashi, Tetsuya Kaiso, Kimitoshi Ikeda, Tim Overend and Donald BanerjiMitsuaki Sekiya1Juntendo University, Bunkyo-ku, Tokyo, JapanTomotaka Kawayama2Kurume University, Kurume-city, Fukuoka, JapanYoshinosuke Fukuchi1Juntendo University, Bunkyo-ku, Tokyo, JapanYota Takahashi3Primary Care, Novartis Pharma K.K.,, Tokyo, JapanTetsuya Kaiso3Primary Care, Novartis Pharma K.K.,, Tokyo, JapanKimitoshi Ikeda3Primary Care, Novartis Pharma K.K.,, Tokyo, JapanTim Overend4Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomDonald Banerji5Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- Once-daily NVA237 improves lung function in COPD patients: Pooled results of the GLOW1 and GLOW2 studiesBy Donald Banerji, Vijay Alagappan, Carmen Martin, Ellie He, Hungta Chen and Tim OverendDonald Banerji1Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesVijay Alagappan2Primary Care, Novartis Horsham Research Centre, Horsham, West Sussex, United KingdomCarmen Martin2Primary Care, Novartis Horsham Research Centre, Horsham, West Sussex, United KingdomEllie He3Integrated Information Sciences (Respiratory), Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesHungta Chen3Integrated Information Sciences (Respiratory), Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesTim Overend2Primary Care, Novartis Horsham Research Centre, Horsham, West Sussex, United Kingdom
- Once-daily NVA237 reduces exacerbations and improves symptoms in COPD patients: A pooled analysis of the GLOW1 and GLOW2 studiesBy Donald Banerji, Vijay Alagappan, Carmen Martin, Ellie He, Hungta Chen and Tim OverendDonald Banerji1Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesVijay Alagappan2Primary Care, Novartis Horsham Research Centre, Horsham, West Sussex, United KingdomCarmen Martin2Primary Care, Novartis Horsham Research Centre, Horsham, West Sussex, United KingdomEllie He3Integrated Information Sciences (Respiratory), Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesHungta Chen3Integrated Information Sciences (Respiratory), Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesTim Overend2Primary Care, Novartis Horsham Research Centre, Horsham, West Sussex, United Kingdom
- Once-daily QVA149 significantly improves lung function and symptoms compared to twice-daily fluticasone/salmeterol in COPD patients: The ILLUMINATE studyBy Claus Vogelmeier, Eric Bateman, John Pallante, Hannah Bryant, Vijay Alagappan, Peter D'Andrea, Ellie He and Donald BanerjiClaus Vogelmeier1Department for Respiratory Diseases, University of Marburg, Marburg, GermanyEric Bateman2Department of Medicine, University of Cape Town, South AfricaJohn Pallante3Respiratory Department, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesHannah Bryant4Respiratory Department, Novartis Horsham Research Centre, Horsham, United KingdomVijay Alagappan4Respiratory Department, Novartis Horsham Research Centre, Horsham, United KingdomPeter D'Andrea3Respiratory Department, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesEllie He3Respiratory Department, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesDonald Banerji3Respiratory Department, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- Once-daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe-to-very severe COPD: The SPARK studyBy Marc Decramer, Jadwiga A. Wedzicha, Joachim H. Ficker, Angel FowlerTaylor, Peter D'Andrea, Christie Arrasate, Hungta Chen and Donald BanerjiMarc Decramer1Respiratory Division, University Hospitals, Leuven, BelgiumJadwiga A. Wedzicha2Centre for Respiratory Medicine, University College, London, United KingdomJoachim H. Ficker3Department of Respiratory Medicine, Allergology, and Sleep Medicine, Klinikum Nuernberg, Nuernberg, GermanyAngel FowlerTaylor4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesPeter D'Andrea4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesChristie Arrasate4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesHungta Chen4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesDonald Banerji4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK studyBy Joachim H. Ficker, Jadwiga A. Wedzicha, Marc Decramer, Angel FowlerTaylor, Peter D'Andrea, Christie Arrasate, Hungta Chen and Donald BanerjiJoachim H. Ficker1Department of Respiratory Medicine, Allergology, and Sleep Medicine, Klinikum Nuernberg, Nuernberg, GermanyJadwiga A. Wedzicha2Centre for Respiratory Medicine, University College, London, United KingdomMarc Decramer3Respiratory Division, University Hospitals, Leuven, BelgiumAngel FowlerTaylor4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesPeter D'Andrea4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesChristie Arrasate4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesHungta Chen4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesDonald Banerji4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- Once-daily QVA149 has a good safety profile in patients with COPDBy Tobias Welte, Claus Vogelmeier, Ronald Dahl, Kenneth R. Chapman, Michael Rudolf, Rajendra Mehta, Peter D'Andrea, Hungta Chen and Donald BanerjiTobias Welte1Department of Respiratory Medicine, Hannover Medical School, Hanover, GermanyClaus Vogelmeier2Department of Respiratory Medicine, Universitätsklinikum Gießen Und Marburg, Marburg, GermanyRonald Dahl3Department of Respiratory Diseases, Aarhus University Hospital, Aarhus, DenmarkKenneth R. Chapman4Asthma and Airway Center, University of Toronto, Toronto, CanadaMichael Rudolf5Department of Respiratory Medicine, Ealing Hospital, Middlesex, United KingdomRajendra Mehta6Allergy and Asthma Care, Allergy & Asthma Care and Research Centre, Indore, IndiaPeter D'Andrea7Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesHungta Chen7Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesDonald Banerji7Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- Once-daily QVA149 demonstrates superior improvements in patient-reported dyspnea compared to tiotropium in patients with moderate-to-severe COPD: The BLAZE studyBy Donald A. Mahler, Marc Decramer, Anthony D'Urzo, Heinrich Worth, Tracy White, Vijay Alagappan, Hungta Chen, Karoly Kulich, Nicola Gallagher and Donald BanerjiDonald A. Mahler1Department of Medicine, Geisel School of Medicine, Dartmouth, Hanover, United StatesMarc Decramer2Department of Respiratory Medicine, University Hospital, Katholieke Universiteit, Leuven, BelgiumAnthony D'Urzo3Department of Family and Community Medicine, University of Toronto, Toronto, CanadaHeinrich Worth4Departments of Pulmonology and Cardiology, Hospital Fürth, University Erlangen-Nürnberg, Fürth, GermanyTracy White5Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesVijay Alagappan5Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesHungta Chen5Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesKaroly Kulich6Primary Care, Novartis Pharma AG, Basel, SwitzerlandNicola Gallagher7Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomDonald Banerji5Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting β2-agonist/inhaled corticosteroid (LABA/ICS): The ILLUMINATE studyBy Karen Mezzi, Danny McBryan, John Pallante, Vijay Alagappan, Hungta Chen and Donald BanerjiKaren Mezzi1Primary Care, Novartis Pharma AG, Basel, SwitzerlandDanny McBryan1Primary Care, Novartis Pharma AG, Basel, SwitzerlandJohn Pallante2Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesVijay Alagappan2Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesHungta Chen2Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesDonald Banerji2Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- Once-daily QVA149 provides superior improvements in lung function compared with glycopyrronium and tiotropium in severe COPD patients: A 52 week pooled analysisBy Donald Banerji, Angel FowlerTaylor, Pearl Kho, Hungta Chen and Vijay AlagappanDonald Banerji1Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesAngel FowlerTaylor1Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesPearl Kho1Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesHungta Chen1Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesVijay Alagappan1Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- Once-daily QVA149 provides the same efficacy as the free combination of its monocomponents indacaterol and glycopyrronium: The BEACON studyBy Ronald Dahl, Dalal Jadayel, Vijay Alagappan, Hungta Chen and Donald BanerjiRonald Dahl1Department of Respiratory Medicine, Aarhus University Hospital, Aarhus, DenmarkDalal Jadayel2Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomVijay Alagappan3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesHungta Chen3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesDonald Banerji3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- QVA149 provides superior peak lung function in patients with COPDBy Neil Barnes, Shu Hashimoto, Takahide Nagase, Hungta Chen, Nicola Gallagher, Peter D'Andrea, Vijay Alagappan and Donald BanerjiNeil Barnes1Department of Respiratory Medicine, London Chest Hospital, London, United KingdomShu Hashimoto2Division of Respiratory Medicine, Nihon University School of Medicine, Tokyo, JapanTakahide Nagase3Department of Respiratory Medicine, University of Tokyo, Tokyo, JapanHungta Chen4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesNicola Gallagher5Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomPeter D'Andrea4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesVijay Alagappan4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesDonald Banerji4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- Once-daily QVA149 improves symptom scores in patients with COPDBy Tobias Welte, Ronald Dahl, Hungta Chen, Nicola Gallagher, Peter D'Andrea, Vijay Alagappan and Donald BanerjiTobias Welte1Department of Respiratory Medicine, Hannover Medical School, Hannover, GermanyRonald Dahl2Department of Respiratory Diseases, Aarhus University Hospital, Aarhus, DenmarkHungta Chen3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesNicola Gallagher4Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomPeter D'Andrea3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesVijay Alagappan3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesDonald Banerji3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- QVA149 does not increase the risk of cardio- and cerebro-vascular events, pneumonia and exacerbation events compared with placebo: A network meta-analysis across multiple safety databasesBy Hungta Chen, Peter D'Andrea and Donald BanerjiHungta Chen1Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, United StatesPeter D'Andrea1Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, United StatesDonald Banerji1Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, United States
- Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trialsBy Donald Banerji, Vijay Alagappan, Yulia Green, Nicola Gallagher, Angel FowlerTaylor, Peter D'Andrea and Hungta ChenDonald Banerji1Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesVijay Alagappan1Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesYulia Green2Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomNicola Gallagher2Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomAngel FowlerTaylor1Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesPeter D'Andrea1Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesHungta Chen1Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- Examination of variations in responder rates in COPD clinical trial outcomesBy Paul Jones, Marc Decramer, Jadwiga A. Wedzicha and Donald BanerjiPaul Jones1Division of Clinical Science, St George's, University of London, London, United KingdomMarc Decramer2Respiratory Division, University Hospital, University of Leuven, Leuven, BelgiumJadwiga A. Wedzicha3Centre for Respiratory Medicine, Royal Free Campus, London, United KingdomDonald Banerji4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- QVA149 provides a rapid onset of action which is sustained throughout treatment in patients with COPDBy Ronald Dahl, Nicola Gallagher, Yulia Green, Hannah Bryant, Hungta Chen, Peter D'Andrea, Vijay Alagappan and Donald BanerjiRonald Dahl1Department of Respiratory Medicine, Aarhus University Hospital, Aarhus, DenmarkNicola Gallagher2Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomYulia Green2Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomHannah Bryant2Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomHungta Chen3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesPeter D'Andrea3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesVijay Alagappan3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesDonald Banerji3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- Dual bronchodilation with QVA149 and the free combination of indacaterol and glycopyrronium are equally safe and well tolerated in patients with COPD: The BEACON studyBy Ronald Dahl, Dalal Jadayel, Vijay Alagappan, Hungta Chen and Donald BanerjiRonald Dahl1Department of Respiratory Medicine, Aarhus University Hospital, Aarhus, DenmarkDalal Jadayel2Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomVijay Alagappan3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesHungta Chen3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesDonald Banerji3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: The FLAME studyBy Jadwiga A. Wedzicha, Marc Decramer, Jørgen Vestbo, Nicola Gallagher, Han-Joo Kim, Danny McBryan and Donald BanerjiJadwiga A. Wedzicha1Department of Academic Respiratory Medicine, University College London, Royal Free Campus, London, United KingdomMarc Decramer2Respiratory Division, University Hospitals, University of Leuven, Leuven, BelgiumJørgen Vestbo3Respiratory Research Group, Manchester Academic Health Sciences Centre, Manchester, United KingdomNicola Gallagher4Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomHan-Joo Kim5Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesDanny McBryan6Primary Care, Novartis Pharma AG, Basel, SwitzerlandDonald Banerji5Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK studyBy Joachim H. Ficker, Jadwiga A. Wedzicha, Marc Decramer, Angel FowlerTaylor, Peter D'Andrea, Christie Arrasate, Hungta Chen and Donald BanerjiJoachim H. Ficker1Department of Respiratory Medicine, Allergology, and Sleep Medicine, Klinikum Nuernberg, Nuernberg, GermanyJadwiga A. Wedzicha2Centre for Respiratory Medicine, University College, London, United KingdomMarc Decramer3Respiratory Division, University Hospitals, Leuven, BelgiumAngel FowlerTaylor4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesPeter D'Andrea4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesChristie Arrasate4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesHungta Chen4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesDonald Banerji4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- QVA149 once-daily is safe and well tolerated and improves lung function and health status in Japanese patients with COPD: The ARISE studyBy Kazuhisa Asai, Yoshiaki Minakata, Kazuto Hirata, Yoshinosuke Fukuchi, Tetsuji Kitawaki, Kimitoshi Ikeda and Donald BanerjiKazuhisa Asai1Department of Respiratory Medicine, Graduate School of Medicine, Osaka City University, Osaka, JapanYoshiaki Minakata2Third Department of Internal Medicine, Wakayama Medical University, Wakayama, JapanKazuto Hirata1Department of Respiratory Medicine, Graduate School of Medicine, Osaka City University, Osaka, JapanYoshinosuke Fukuchi3Department of Respiratory Medicine, Juntendo University School of Medicine, Tokyo, JapanTetsuji Kitawaki4Primary Care Clinical Franchise, Novartis Pharma K.K., Tokyo, JapanKimitoshi Ikeda4Primary Care Clinical Franchise, Novartis Pharma K.K., Tokyo, JapanDonald Banerji5Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- Safety of once-daily glycopyrronium in patients with severe-to-very severe COPD: The SPARK studyBy Marc Decramer, Jadwiga A. Wedzicha, Joachim H. Ficker, Angel FowlerTaylor, Peter D'Andrea, Christie Arrasate, Hungta Chen and Donald BanerjiMarc Decramer1Respiratory Division, University Hospitals, Leuven, BelgiumJadwiga A. Wedzicha2Centre for Respiratory Medicine, University College, London, United KingdomJoachim H. Ficker3Department of Respiratory Medicine, Allergology, and Sleep Medicine, Klinikum Nuernberg, Nuernberg, GermanyAngel FowlerTaylor4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesPeter D'Andrea4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesChristie Arrasate4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesHungta Chen4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesDonald Banerji4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- Cardio- and cerebro-vascular safety of QVA149: Results from a pooled analysisBy Gary T. Ferguson, Neil Barnes, Rajendra Mehta, Peter D'Andrea, Hungta Chen and Donald BanerjiGary T. Ferguson1Pulmonology, Pulmonary Research Institute of Southeast Michigan, Livonia, United StatesNeil Barnes2Department of Respiratory Medicine, London Chest Hospital, Barts Health NHS Trust, London, United KingdomRajendra Mehta3Allergy and Asthma Care, Allergy & Asthma Care and Research Centre, Indore, IndiaPeter D'Andrea4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, United StatesHungta Chen4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, United StatesDonald Banerji4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, United States
- Development and validation of an innovative self-administered computerized (SAC) version of baseline/transition dyspnea index (BDI/TDI) for evaluating breathlessness in patients with COPD: The BLAZE studyBy Donald A. Mahler, Vanessa Brunel, Tracy White, Vijay Alagappan, Hungta Chen, Karoly Kulich, Nicola Gallagher and Donald BanerjiDonald A. Mahler1Department of Medicine, Geisel School of Medicine, Dartmouth, Hanover, United StatesVanessa Brunel2Linguistic Validation, MAPI Institute, Lyon, FranceTracy White3Primary Care, Novartis Pharmaceutical Corporation, East Hanover, NJ, United StatesVijay Alagappan3Primary Care, Novartis Pharmaceutical Corporation, East Hanover, NJ, United StatesHungta Chen3Primary Care, Novartis Pharmaceutical Corporation, East Hanover, NJ, United StatesKaroly Kulich4Primary Care, Novartis Pharma AG, Basel, SwitzerlandNicola Gallagher5Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomDonald Banerji3Primary Care, Novartis Pharmaceutical Corporation, East Hanover, NJ, United States
- Once-daily QVA149 provides clinically meaningful improvements in lung function and clinical outcomesBy Claus Vogelmeier, Ronald Dahl, Anthony D'Urzo, Hungta Chen, Yulia Green and Donald BanerjiClaus Vogelmeier1Department of Respiratory Medicine, Universitätsklinikum Gießen Und Marburg, Marburg, GermanyRonald Dahl2Department of Respiratory Diseases, Aarhus University Hospital, Aarhus, DenmarkAnthony D'Urzo3Department of Family and Community Medicine (DFCM), University of Toronto, Ontario, CanadaHungta Chen4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesYulia Green5Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomDonald Banerji4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK studyBy Jadwiga A. Wedzicha, Marc Decramer, Joachim H. Ficker, Dennis Niewohner, Thomas Sandström, Angel FowlerTaylor and Donald BanerjiJadwiga A. Wedzicha1Centre for Respiratory Medicine, University College London, London, United KingdomMarc Decramer2Respiratory Division, University of Leuven, Leuven, BelgiumJoachim H. Ficker3Department of Respiratory Medicine, Allergology, Sleep Medicine, Klinikum Nuernberg, Nuernberg, GermanyDennis Niewohner4Lungmottagningen, MedicinCentrum, Norrlands Universitetssjukhus, Umea, SwedenThomas Sandström5Pulmonary Section, VA Medical Center, Minneapolis, MN, United StatesAngel FowlerTaylor6Primary Care, Novartis Pharmaceuticals, East Hanover, NJ, United StatesDonald Banerji6Primary Care, Novartis Pharmaceuticals, East Hanover, NJ, United States
- Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: BLAZE studyBy Donald A Mahler, Marc Decramer, Anthony D'Urzo, Heinrich Worth, Tracy White, Vijay K. T. Alagappan, Hungta Chen, Nicola Gallagher, Károly Kulich and Donald BanerjiArticle | Published in 2013 in European Respiratory JournalDonald A Mahler*Section of Pulmonary & Critical Care Medicine; Geisel School of Medicine at Dartmouth; Hanover, NH, USAMarc Decramer#Division of Respiratory Medicine, University Hospital, Katholieke Universiteit, Leuven, BelgiumAnthony D'Urzo¶Dept of Family and Community Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, CanadaHeinrich Worth+Depts of Pneumology and Cardiology, Hospital Fürth, University Erlangen-Nürnberg, Fürth, GermanyTracy White§Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAVijay K. T. Alagappan§Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAHungta Chen§Novartis Pharmaceuticals Corporation, East Hanover, NJ, USANicola GallagherfNovartis Horsham Research Centre, Horsham, UKKároly Kulich**Novartis Pharma AG, Basel, SwitzerlandDonald Banerji§Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
- Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyBy Eric D Bateman, Gary T Ferguson, Neil Barnes, Nicola Gallagher, Yulia Green, Michelle Henley and Donald BanerjiArticle | Published in 2013 in European Respiratory JournalEric D Bateman*Dept of Medicine, University of Cape Town, Cape Town, South AfricaGary T Ferguson#Pulmonary Research Institute of Southeast Michigan, Livonia, Michigan, USANeil Barnes¶London Chest Hospital, Barts Health NHS Trust, London, UKNicola Gallagher+Novartis Horsham Research Centre, Horsham, UKYulia Green+Novartis Horsham Research Centre, Horsham, UKMichelle Henley+Novartis Horsham Research Centre, Horsham, UKDonald Banerji§Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA
- Once-daily glycopyrronium improves lung function and reduces exacerbations in severe-to-very severe COPD patients: The SPARK studyBy Jadwiga A. Wedzicha, Marc Decramer, Joachim H. Ficker, Angel FowlerTaylor, Peter D'Andrea, Christie Arrasate, Hungta Chen and Donald BanerjiJadwiga A. Wedzicha1Centre for Respiratory Medicine, University College London, London, United KingdomMarc Decramer2Respiratory Division, University Hospitals, Leuven, BelgiumJoachim H. Ficker3Department of Respiratory Medicine, Allergology, and Sleep Medicine, Klinikum Nuernberg, Nuernberg, GermanyAngel FowlerTaylor4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesPeter D'Andrea4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesChristie Arrasate4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesHungta Chen4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesDonald Banerji4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- Addressing unmet needs in the treatment of COPDBy Francesco Patalano, Donald Banerji, Peter D’Andrea, Robert Fogel, Pablo Altman and Paul ColthorpeFrancesco Patalano1Novartis Pharma AG, Basel, Switzerland. 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.Donald Banerji1Novartis Pharma AG, Basel, Switzerland. 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.Peter D’Andrea1Novartis Pharma AG, Basel, Switzerland. 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.Robert Fogel1Novartis Pharma AG, Basel, Switzerland. 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.Pablo Altman1Novartis Pharma AG, Basel, Switzerland. 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.Paul Colthorpe1Novartis Pharma AG, Basel, Switzerland. 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
- QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: The SPARK studyBy Jadwiga A. Wedzicha, Marc Decramer, Petter Olsson, Hungta Chen, Robert Fogel and Donald BanerjiJadwiga A. Wedzicha1Centre for Respiratory Medicine, University College London, London, United KingdomMarc Decramer2Respiratory Division, University of Leuven, Leuven, BelgiumPetter Olsson3Primary Care, Novartis Pharma AG, Basel, SwitzerlandHungta Chen4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,Robert Fogel4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,Donald Banerji4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,
- QVA149 showed significant improvements in lung function and health status and was well tolerated versus glycopyrronium and tiotropium in patients with severe COPD: The SPARK studyBy Jadwiga A. Wedzicha, Anthony D'Urzo, Karen Mezzi, Hungta Chen, Donald Banerji and Robert FogelJadwiga A. Wedzicha1Centre for Respiratory Medicine, University College London, Royal Free Hospital, London, United KingdomAnthony D'Urzo2Department of Family and Community Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, CanadaKaren Mezzi3Primary Care, Novartis Pharma AG, Basel, SwitzerlandHungta Chen4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,Donald Banerji4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,Robert Fogel4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,
- Late-breaking abstract: Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol/fluticasone combination (SFC) in patients with COPD: The LANTERN studyBy Nanshan Zhong, Changzheng Wang, Xiangdong Zhou, Nuofu Zhang, Francesco Patalano, Michael Humphries, Linda Wang and Donald BanerjiNanshan Zhong1Department of Respiratory Medicine, Guangzhou Institute of Respiratory Diseases, First Affiliated Hospital , Guangzhou Medical University, Guangzhou, Guangdong, ChinaChangzheng Wang2Institute of Respiratory Disease, Xin Qiao Hospital, Third Military Medical University, Chongqing City, Chongqing, ChinaXiangdong Zhou3Department of Respiratory Medicine, Southwest Hospital, Third Military Medical University, Chongqing City, Chongqing, ChinaNuofu Zhang1Department of Respiratory Medicine, Guangzhou Institute of Respiratory Diseases, First Affiliated Hospital , Guangzhou Medical University, Guangzhou, Guangdong, ChinaFrancesco Patalano4Primary Care, Novartis Pharma AG, Basel, SwitzerlandMichael Humphries5Primary Care, Beijing Novartis Pharma Co. Ltd., Shanghai, ChinaLinda Wang5Primary Care, Beijing Novartis Pharma Co. Ltd., Shanghai, ChinaDonald Banerji6Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,
- Effect of QVA149 on lung function in the subgroup of patients with a history of exacerbations in the previous year and baseline ICS use from the SHINE studyBy Kenneth R. Chapman, Eric D. Bateman, Petter Olsson, Hungta Chen, Donald Banerji and Robert FogelKenneth R. Chapman1Asthma and Airway Centre, University Health Network, University of Toronto, Ontario, CanadaEric D. Bateman2Department of Medicine, University of Cape Town, Cape Town, South AfricaPetter Olsson3Primary Care, Novartis Pharma AG, Basel, SwitzerlandHungta Chen4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,Donald Banerji4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,Robert Fogel4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,
- Cardio- and cerebrovascular safety of QVA149 in patients with moderate-to-very severe COPD: A pooled analysisBy Ronald Dahl, Roland Buhl, Karen Mezzi, Agnes Schubert-Tennigkeit, Hungta Chen, Donald Banerji and Robert FogelRonald Dahl1Department of Dermatology, Allergy Centre, Odense University Hospital, Odense, DenmarkRoland Buhl2Pulmonary Department, Mainz University Hospital, Mainz, GermanyKaren Mezzi3Primary Care, Novartis Pharma AG, Basel, SwitzerlandAgnes Schubert-Tennigkeit3Primary Care, Novartis Pharma AG, Basel, SwitzerlandHungta Chen4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,Donald Banerji4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,Robert Fogel4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,
- QVA149 improves dyspnoea and lung function versus tiotropium in symptomatic patients using LABA/ICS preceding study enrolment: The BLAZE studyBy Anthony D'Urzo, Donald A. Mahler, Caglar Karakurum, Hungta Chen, Robert Fogel and Donald BanerjiAnthony D'Urzo1Department of Family and Community Medicine, University of Toronto, Toronto, ON, CanadaDonald A. Mahler2Section of Pulmonary and Critical Care Medicine, Geisel School of Medicine at Dartmouth, Hanover, NH,Caglar Karakurum3Primary Care, Novartis Pharma AG, Basel, SwitzerlandHungta Chen4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,Robert Fogel4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,Donald Banerji4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,
- Once-daily QVA149 improves dyspnoea, lung function and reduces rescue medication use in symptomatic patients with COPD using LAMA as prior medication: The BLAZE studyBy Anthony D'Urzo, Donald A. Mahler, Petter Olsson, Hungta Chen, Robert Fogel and Donald BanerjiAnthony D'Urzo1Department of Family and Community Medicine, University of Toronto, Toronto, ON, CanadaDonald A. Mahler2Section of Pulmonary & Critical Care Medicine, Geisel School of Medicine, Dartmouth, NH,Petter Olsson3Primary Care, Novartis Pharma AG, Basel, SwitzerlandHungta Chen4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,Robert Fogel4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,Donald Banerji4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,
- Relationship between change in trough FEV1 and COPD patient outcomes: Pooled analysis of 23 clinical trials in patients with COPDBy James F. Donohue, Paul Jones, Christian Bartels, Jessica Marvel, Peter D'Andrea, Donald Banerji, Francesco Patalano and Robert FogelJames F. Donohue1Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC United StatesPaul Jones2Division of Clinical Science, St George's University of London, London, United KingdomChristian Bartels3Respiratory, Novartis Pharma AG, Basel, SwitzerlandJessica Marvel4Respiratory, Novartis Pharmaceuticals Corporation, East Hanover, NJ United StatesPeter D'Andrea4Respiratory, Novartis Pharmaceuticals Corporation, East Hanover, NJ United StatesDonald Banerji4Respiratory, Novartis Pharmaceuticals Corporation, East Hanover, NJ United StatesFrancesco Patalano3Respiratory, Novartis Pharma AG, Basel, SwitzerlandRobert Fogel4Respiratory, Novartis Pharmaceuticals Corporation, East Hanover, NJ United States
- QVA149 compared with salmeterol/fluticasone (SFC) on exacerbations and its correlation with baseline blood eosinophils: A pooled analysis of LANTERN and ILLUMINATEBy Jadwiga A. Wedzicha, David Price, Karen Mezzi, Robert Fogel and Donald BanerjiJadwiga A. Wedzicha1National Heart and Lung Institute, Imperial College London, London, United KingdomDavid Price2Primary Care Respiratory Medicine, University of Aberdeen, Aberdeen, United KingdomKaren Mezzi3Respiratory, Novartis Pharma AG, Basel, SwitzerlandRobert Fogel4Respiratory, Novartis Pharmaceuticals Corporation, East Hanover, NJ United StatesDonald Banerji4Respiratory, Novartis Pharmaceuticals Corporation, East Hanover, NJ United States
- Once-daily QVA149 improves lung function and health status versus twice-daily salmeterol/fluticasone (SFC) in symptomatic GOLD B and GOLD D COPD patients: LANTERN/ILLUMINATE pooled analysisBy Claus Vogelmeier, Nanshan Zhong, Karen Mezzi, Robert Fogel and Donald BanerjiClaus Vogelmeier1Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-Universität Marburg, Marburg, GermanyNanshan Zhong2State Key Laboratory of Respiratory Diseases, First Affiliated Hospital, Guangzhou Medical University, Guangzhou, ChinaKaren Mezzi3Respiratory, Novartis Pharma AG, Basel, SwitzerlandRobert Fogel4Respiratory, Novartis Pharmaceuticals Corporation, East Hanover, NJ United StatesDonald Banerji4Respiratory, Novartis Pharmaceuticals Corporation, East Hanover, NJ United States
- QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trialsBy Donald Mahler, Dorothy Keininger, Robert Fogel, Karen Mezzi and Donald BanerjiDonald Mahler1Medicine, Geisel School of Medicine, Hanover, NH United StatesDorothy Keininger2Respiratory, Novartis Pharma AG, Basal, SwitzerlandRobert Fogel3Respiratory, Novartis Pharmaceuticals Corporation, East Hanover, NJ United StatesKaren Mezzi2Respiratory, Novartis Pharma AG, Basal, SwitzerlandDonald Banerji3Respiratory, Novartis Pharmaceuticals Corporation, East Hanover, NJ United States
- Baseline symptom scores and future risk of severe exacerbation: The SPARK studyBy Jadwiga A. Wedzicha, Karen Mezzi, Robert Fogel and Donald BanerjiJadwiga A. Wedzicha1National Heart and Lung Institute, Imperial College London, London, United KingdomKaren Mezzi2Respiratory, Novartis Pharma AG, Basel, SwitzerlandRobert Fogel3Respiratory, Novartis Pharmaceuticals Corporation, East Hanover, NJ United StatesDonald Banerji3Respiratory, Novartis Pharmaceuticals Corporation, East Hanover, NJ United States
- QVA149 provides significant symptomatic benefit to COPD patients as measured by a new symptom e-diary: The SHINE studyBy Hanns-Christian Tillmann, Ieuan Jones, Robert Fogel and Donald BanerjiHanns-Christian Tillmann1Respiratory, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, SwitzerlandIeuan Jones2Development IIS, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, SwitzerlandRobert Fogel3Respiratory, Novartis Pharmaceuticals Corporation, East Hanover, NJ United StatesDonald Banerji3Respiratory, Novartis Pharmaceuticals Corporation, East Hanover, NJ United States
- Efficacy and safety of QVA149 compared with salmeterol/fluticasone combination (SFC) in Chinese patients with moderate-to-severe COPD: A subgroup analysis from the LANTERN studyBy Nanshan Zhong, Changzheng Wang, Xiangdong Zhou, Nuofu Zhang, Francesco Patalano, Michael Humphries, Linda Wang and Donald BanerjiNanshan Zhong1State Key Laboratory of Respiratory Diseases, First Affiliated Hospital, Guangzhou Medical University, Guangzhou, ChinaChangzheng Wang2Institute of Respiratory Disease, Xin Qiao Hospital, Third Military Medical University, Chongqing City, ChinaXiangdong Zhou3Department of Respiratory Medicine, Southwest Hospital, Third Military Medical University, Chongqing City, ChinaNuofu Zhang1State Key Laboratory of Respiratory Diseases, First Affiliated Hospital, Guangzhou Medical University, Guangzhou, ChinaFrancesco Patalano4Respiratory, Novartis Pharma AG, Basel, SwitzerlandMichael Humphries5Respiratory, Beijing Novartis Pharma Co. Ltd., Shanghai, SwitzerlandLinda Wang5Respiratory, Beijing Novartis Pharma Co. Ltd., Shanghai, SwitzerlandDonald Banerji6Respiratory, Novartis Pharmaceuticals Corporation, East Hanover, NJ United States
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.
